echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The 9th domestic Yuheng Pharmaceutical LAG3 monoclonal antibody was approved for clinical use

    The 9th domestic Yuheng Pharmaceutical LAG3 monoclonal antibody was approved for clinical use

    • Last Update: 2022-05-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Cube Info

    Author: sunshine

    On April 19, the CDE official website showed that Yuheng Pharmaceutical's recombinant fully human anti-LAG-3 monoclonal antibody injection was approved for clinical use in the treatment of advanced malignant tumors


    LAG3 is an immune checkpoint that is the same inhibitory target as PD-1


    In November 2017, Yuheng Pharmaceutical and WuXi Biologics reached a cooperation to jointly develop an anti-LAG3 fully human innovative antibody drug


    At present, 9 drugs targeting LAG3 have entered the clinical stage in China


    In addition, there are a number of LAG3/PD(L)1 dual antibodies in China that are conducting relevant clinical trials, namely IBI323 from Innovent, RO7247669 from Roche, MGD013 from Zai Lab/MacroGenics, EMB-02 from Anima Bio, and Merck & Co.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.